Encapsulate Closes $1.8M Oversubscribed Seed Round to Accelerate Personalized Cancer Therapy
Farmington, CT – Encapsulate, a developer of personalized oncology solutions, has raised $1.8 million in seed funding, led by Blackwood Healthcare Breakthroughs, Ambit Health Ventures, and CT Innovations.
Encapsulate’s technology transforms a tiny slice of a patient’s tumor tissue into many microtumors, then conducts different tests on each microtumor. Encapsulate’s platform can provide individualized treatment recommendations in as few as seven days.
“Our Tumor-on-a-Chip system provides precise, evidence-based insights that will empower oncologists to deliver the optimal treatment to each patient,” said Dr. Armin Rad, CEO of Encapsulate. “Every cancer patient’s tumor is unique, and patients deserve unique solutions.”
“We are thrilled to partner with the dynamic Encapsulate team as they advance this critical solution for cancer patients and their care teams,” said Mason Reiner, Partner at Ambit Health Ventures.
“While many companies work on personalized cancer treatments, Encapsulate validates its recommendations on a patient’s own tumor cells,” said Chris Willenken, Partner at Blackwood Healthcare Breakthroughs. “This evidence-based approach improves accuracy and reduces risk.”
Investors in this round include CT Innovations, Connecticut’s leading source of financing and ongoing support for innovative, growing companies; Blackwood Healthcare Breakthroughs, an investor in early-stage MedTech startups that aim to revolutionize standards of care; and Ambit Health Ventures, an early-stage venture capital fund that invests in transformative healthcare solutions.
